The transcription factor p53 is an important tumour suppressor that is lost or mutated in more than 50% of human cancers, and multiple oncogenic mechanisms lead to its degradation by the proteasome 1,2 . Consequently, stabilization and (re-)activation of p53 is a key aim of pharmaceutical research. One strategy focuses on targeting the oncogenic ubiquitin E3 ligase MDM2, which binds, ubiquitinates, and destabilizes p53 2, 3 . MDM2 inhibitors such as Nutlins prevent the MDM2-p53 interaction and p53 loss, with encouraging pre-clinical results 2 . MDM2 is protected from autoubiquitination and degradation by the deubiquitinase USP7 4,5 , and genetic or chemical interference with USP7 function destabilizes MDM2 and increases levels of p53 [4] [5] [6] . Small-molecule inhibitors have been reported that target USP7 with a relatively narrow dynamic range (20-40 μ M for P22077 or P5091, and 25-50 μ M for HBX41108). Although they also inhibit related and unrelated enzymes 7-9 , treatment with P22077 or P5091 leads to MDM2 destabilization and p53 stabilization 8, [10] [11] [12] [13] [14] , resulting in tumour cell death in vivo [15] [16] [17] . P5091 is able to overcome resistance to proteasome inhibition by bortezomib in multiple myeloma cells that overexpress USP7
The transcription factor p53 is an important tumour suppressor that is lost or mutated in more than 50% of human cancers, and multiple oncogenic mechanisms lead to its degradation by the proteasome 1, 2 . Consequently, stabilization and (re-)activation of p53 is a key aim of pharmaceutical research. One strategy focuses on targeting the oncogenic ubiquitin E3 ligase MDM2, which binds, ubiquitinates, and destabilizes p53 2, 3 . MDM2 inhibitors such as Nutlins prevent the MDM2-p53 interaction and p53 loss, with encouraging pre-clinical results 2 . MDM2 is protected from autoubiquitination and degradation by the deubiquitinase USP7 4, 5 , and genetic or chemical interference with USP7 function destabilizes MDM2 and increases levels of p53 [4] [5] [6] . Small-molecule inhibitors have been reported that target USP7 with a relatively narrow dynamic range (20-40 μ M for P22077 or P5091, and 25-50 μ M for HBX41108). Although they also inhibit related and unrelated enzymes [7] [8] [9] , treatment with P22077 or P5091 leads to MDM2 destabilization and p53 stabilization 8, [10] [11] [12] [13] [14] , resulting in tumour cell death in vivo [15] [16] [17] . P5091 is able to overcome resistance to proteasome inhibition by bortezomib in multiple myeloma cells that overexpress USP7 12 . Consequently, these compounds reduce medulloblastoma, colorectal and lung tumour growth in mice 13, 18, 19 , but it is unclear whether these effects are solely attributable to USP7 target modulation.
Discovery of specific USP7 inhibitors
We identified USP7 inhibitors using a ubiquitin-rhodamine assay 20 , screening the inhibitory potential of a diverse collection of approximately 500,000 compounds available at FORMA Therapeutics 21 . From this, we identified several primary hits that were further validated for direct USP7 binding by biophysical techniques such as surface plasmon resonance (SPR). Optimization of the original hits with respect to activity and physicochemical properties resulted in the prioritization of a pyrazolo [3,4-d] pyrimidin-4-one-piperidine (PyrzPPip) series 21 .
Within the series, we identified a covalent inhibitor, FT827, and a non-covalent inhibitor, FT671 (Fig. 1a) . FT671 and FT827 bind to the USP7 catalytic domain (USP7 CD ; residues 208-560; Extended Data . 1c ). FT827 features a vinylsulfonamide moiety that covalently modifies the catalytic Cys223 of USP7 and inhibits the enzyme with an enzyme inactivation rate (k inact ) to inhibition constant (K i ) ratio (k inact /K i ) of 66 ± 25 M −1 s −1 (Fig. 1a , Extended Data Fig. 1d , Methods). FT671 and FT827 exclusively inhibit USP7 in a panel of 38 deubiquitinases (DUBs) from diverse families (Fig. 1b , Extended Data Table 1 ). We also tested Article reSeArcH FT671 against USP47 and USP10, two enzymes inhibited by P5091 and P22077 7, 9 , but found no effect on their activity (Extended Data Table 1 ). To test compound specificity in a cellular context, we incubated FT827 or FT671 with either crude cell extracts or with intact MCF7 breast cancer cells, followed by incubation with the ubiquitin active site covalent inhibitor haemagglutinin (HA)-tagged ubiquitin bromoethyl (HA-UbC2Br) 22 ( Fig. 1c, d , Extended Data Fig. 2a , Methods). Both compounds inhibited USP7 probe reactivity with IC 50 values of approxi mately 0.1-2 μ M, confirming 10-100-fold higher potency than P22077 (Extended Data Fig. 2g ). Immunoblotting for the haemagglutinin tag qualitatively indicated that no other DUB was affected (Extended Data Fig. 2 ). This was confirmed by mass spectrometry experiments 7, 23 in which HA-UbC2Br-modified DUBs were immunoprecipitated with an anti-HA antibody, and out of 36 endogenous DUBs identified, 22 were of sufficient abundance to enable quantitative measurements (Fig. 1e, f, Extended Data Fig. 2a, f) . FT671 or FT827 only affected USP7, and not other DUBs including USP47 and USP10 (Fig. 1e, f, Supplementary Tables 1, 2 ). Hence, FT827 and FT671 are bona fide USP7-specific inhibitors.
Structures of USP7-inhibitor complexes
To understand the mechanism and specificity of USP7 inhibitors, USP7 CD crystals were soaked with FT671 and FT827 and co-crystal structures were determined to 2.35 and 2.33 Å resolution, respectively (Fig. 2a, Extended Data Fig. 3 , Extended Data Table 2 ). The USP7 catalytic domain adopts the well-characterized hand-like structure with thumb, fingers and palm subdomains 24 ( Fig. 2a) , and the compounds bind in the thumb-palm cleft that guides the ubiquitin C terminus into the active site ( Fig. 2a-e) . Identical interactions occur between the PyrzPPip scaffold and Asp295, Val296 (backbone) and Gln297 from the thumb subdomain, and Phe409 (backbone) and Tyr465 of the palm subdomain (Fig. 2d, e, Extended Data Fig. 4) . The PyrzPPip scaffold of non-covalent FT671 (Fig. 2d) is extended towards the fingers subdomain by a para-fluorophenyl group, and towards the catalytic centre
Remaining activity (%) Remaining activity (%) USP9x  USP10  USP14  USP15  USP16  USP19  USP24  USP40  USP28  USP32  USP34  USP47  UCHL3  UCHL5  OTUB2  OTUD7B  USP11  OTUB1  0   20 USP5  USP7  USP8  USP9x  USP10  USP14  USP15  USP16  USP19  USP24  USP40  USP28  USP32  USP34  USP47  UCHL3  UCHL5  OTUB2  OTUD7B  USP11  OTUB1  0   20   40   60   80   100   120 140 USP9x  USP11  USP14  USP15  USP16  USP19  USP20  USP21  USP25  USP28  USP30  USP35  USP36  USP45  CYLD  UCHL1  UCHL3  UCHL5  BAP1  OTUD2  OTUB2  OTUD3  pOTUD5  OTUD6A  OTUD6B  OTUD7B  AMSH- Table 1) . c, d, Cell lysates (c) or intact MCF7 cells (d) were incubated with FT671 or FT827, then with HA-UbC2Br probe. Samples were immunoblotted with the USP7 antibody. Modification of USP7 with a ubiquitin probe (USP7~ Ub) was lost with increasing concentrations of inhibitors. One of two independent biological experiments is shown (see Extended Data Fig. 2 ). e, f, HA-based immunoprecipitation of labelled DUBs from experiments in c were subjected to mass spectrometry-based quantification in three technical replicates 7 . Differences in DUB-probe binding were quantified for 22 out of 36 identified DUBs (see Supplementary Tables 1, 2 ). FT827 or FT671 only affect USP7 (see Methods for statistics). Uncropped images for gels are shown in Supplementary Fig. 1 .
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by a 3-fluoropyrazole group that packs against the piperidine group and resides 4.7 Å from the thiol side chain of catalytic Cys223. The covalent compound FT827 (Fig. 2e) is not extended towards the fingers subdomain, but is elongated towards the catalytic centre, enabling the vinylsulfonamide moiety to form a covalent bond with Cys223.
The inhibitor structures highlight the plasticity of USP7, which is known to undergo notable structural changes upon ubiquitin binding 24 . The catalytic Cys223 moves from an incompetent (apo USP7) to a catalytically competent conformation in complex with, for example, ubiquitin aldehyde (UbAl) (Fig. 2b, c) . Further changes in the ubiquitin-binding channel, in particular rotation of a Phe side chain (Phe409 in USP7, Fig. 2b-f) , open a hydrophobic pocket that is occupied by ubiquitin Leu73 24 ( Fig. 2c) . Similar conformations of the Phe409-equivalent residue are observed in all published USP structures (see below, Fig. 2g ).
FT671 and FT827 bind to the inactive apo state of USP7, which is reflected by lower root mean square deviation values of compound-bound versus USP7-apo (0.4 Å) as compared to compound-bound versus USP7~ UbAl structures (0.8-1 Å; the tilde symbol (~ ) indicates a covalent complex) (Figs 2b-e, 3a) . In the USP7~ FT827 structure, the compound has modified the incompetent conformation of Cys223 despite the lack of the deprotonating activity of His464, and Phe409 is in the apo conformation (Fig. 2e, f) . Even more striking is the Phe409 conformation in USP7-FT671, in which the compound has expelled Phe409 to a solvent-exposed conformation not observed previously (Fig. 2d, f) . This highlights surprising plasticity in USP domains in which one of our compounds occupies a pocket not present in either the apo-or ubiquitin-bound USP7 structures. Together, the structures explain the high affinity binding properties of FT671 and FT827, and the location in the ubiquitin-binding site explains their mechanism of action as ubiquitin-competitive small molecules.
Molecular basis for compound specificity
The structures further reveal the molecular basis of the compound speci ficity towards USP7 (Fig. 3, Extended Data Fig. 5 ). USP7 residues that mediate interactions with the inhibitors (Asp295, Val296, Gln297, Phe409 and Tyr465) are highly conserved in most USP enzymes 25 , and sequence differences in the compound-binding site alone do not explain compound specificity. Instead, the reason for the specificity lies in unique structural features of the USP7 thumb subdomain, which contains an allosteric regulatory interaction site known as the switching loop (Fig. 3a) . This loop, located between helices α 4 and α 5 (residues 283-295), allows sufficient space for compound binding in apo USP7. Importantly, the switching loop changes upon ubiquitin binding 24 , when a helical turn straightens and complements the extended ubiquitin C terminus (Figs 2c, 3a) . In the ubiquitin-bound conformation, new hydrogen bonds are formed between Tyr465 and Tyr514 of the palm, and Asp295-Val296 of the thumb subdomain, which rigidify the ubiquitin-binding channel. These contacts between palm subdomain Tyr residues and the thumb subdomain are highly conserved, and importantly, are already formed in all other apo USP structures reported so far (Extended Data Fig. 5b )-that is, in the absence of ubiquitin. Indeed, pre-formed palm-Tyr-thumb contacts and competent catalytic triad residues appear to stabilize other USPs for ubiquitin binding (Extended Data Fig. 5b) .
Here, USP7 is distinct: the switching loop conformation in apo USP7 prevents a Tyr465 thumb interaction (distance 7.9 Å), and the rotated 
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Tyr465 side chain is free to form a hydrogen bond with the compound (Figs 2b, d , e, 3a, c, Extended Data Figs 4, 5). The unrestrained conformation of Tyr465 allows nearby Tyr514 to sit flat in the ubiquitinbinding channel (Fig. 3c, d) , and, in contrast to other USPs, this residue does not interact with the switching loop. Both Tyr conformations create space for compound binding. In all other USP structures, equivalent Tyr residues point into the ubiquitin-binding channel, which would prevent interactions with our compounds (Fig. 3c -e, Extended Data Fig. 5b) . Together, the unique positions of Tyr465 and Tyr514 in the ubiquitin-binding channel, enabled by a unique conformation of the switching loop in apo USP7, allow FT671 and FT827 to specifically target USP7.
Characterization of compound binding
Compound-binding modes were tested by mutational analysis, with the aim to identify compound-resistant USP7 mutants. This was challenging, since most residues involved in compound binding are also involved in ubiquitin binding and/or catalysis, and mutations had detrimental effects on USP7 function. For example, mutation of Tyr465, which forms a hydrogen bond with the compound (Figs 2d, e, 3c-e, see above), abrogated compound binding without affecting the ubiquitin interaction as assessed by SPR (Extended Data Fig. 6a-d) . However, while folded (Extended Data Fig. 6e ), the USP7 CD (Y465N) mutant showed a greatly reduced catalytic efficiency (k cat ) (Fig. 3f , Extended Data Fig. 6f ), rendering it less useful for further analysis. Interestingly, USP7(Q297A), which removes the hydrogen bond with the pyrazolopyrimidin-4-one group of the compound ( ). Finally, we examined the importance of the switching loop directly by mutating Phe291, which does not contact the compounds, but is important for the integrity of the switching loop in apo USP7 (Fig. 3e) . The USP7 CD (F291N) mutant showed strongly reduced compound binding and inhibition (Fig. 3g , Extended Data Fig. 6a, b) , but, in contrast to the other mutants, and in agreement with previous work 26 , showed improved ubiquitin affinity and ubiquitinrhodamine activity (Fig. 3f , Extended Data Fig. 6c, d , f). This supports the notion that mutations in Phe291 shift the equilibrium towards an active USP7 conformation 26 . The switching loop is a point of intrinsic allosteric regulation of USP7 via its own C-terminal region and activating proteins such as GMPS [26] [27] [28] [29] [30] (Extended Data Fig. 6g ). Importantly, FT671 binds and inhibits both USP7 CD and the more active USP7 C-term with identical parameters in vitro (Extended Data Fig. 1c ), and both compounds engage endogenous USP7 in cells (Fig. 1c-f , Extended Data Fig. 2 ). This indicates that USP7 cycles through apo-like structures that can be targeted by our compounds.
Biological activity of FT671
Cell lines derived from colorectal carcinoma (HCT116) or bone osteosarcoma (U2OS) respond to USP7 knockdown with p53 stabilization Article reSeArcH and p21 induction, leading to growth arrest and apoptosis (Extended Data Fig. 7a, b) . Similarly, FT671 increases p53 protein levels in these cell lines (Fig. 4a, b ), leading to induction of p53 target genes including BBC3 (which encodes PUMA), CDKN1A (p21), RPS27L (S27L) and MDM2 (Fig. 4c, Extended Data Fig. 7c ). The increase in p53 correlates with increased MDM2 degradation, which is initially balanced by p53-induced MDM2 expression 31, 32 but has an effect on MDM2 protein levels after prolonged compound treatment (Fig. 4a , Extended Data Fig. 7d ). Overall, these effects are similar to what has been observed with less specific compounds 12, 13, 18, 19 . To verify that the effects on p53 arise from USP7 inhibition, we exploited compound-resistant mutants ( Fig. 3e-g ). Stable HCT116 cell lines expressing a single additional copy of wild-type USP7 or USP7 mutants via a Flp-In TRex system, showed identical p53 induction in control and USP7 wild-type expressing cells after FT671 treatment, but failed to induce p53 when USP7(Q297A) or USP7(F291N) were expressed (Fig. 4d, Extended Data Fig. 7e ).
Numerous substrates of USP7 have been reported, and may be modulated by USP7 inhibition [33] [34] [35] . Indeed, FT671 led to the degradation of N-Myc and upregulation of p53 in the neuroblastoma cell line IMR-32, consistent with a previous report 33 (Extended Data  Fig. 7f ). USP7 is also part of a demethylase complex, and regulates the E3 ligase UHRF1 and the DNA methylase DNMT1 34, 35 . FT671 leads to degradation of both proteins (Extended Data Fig. 7g, h) , showing that their regulation depends on USP7 activity. As such, USP7 inhibitors appear suitable for the study of a variety of other biological contexts.
Physiological responses to FT671
As for other cell lines, FT671 also stabilizes p53 in the MM.1S multiple myeloma cell line (Extended Data Fig. 8a ), which correlates with increased MDM2 ubiquitination (Extended Data Fig. 8b ) and leads to expression of p53 target genes (Extended Data Fig. 8c, d ). FT671 blocks the proliferation of MM.1S cells, with an IC 50 value of 33 nM as determined by the CellTiter-Glo assay (Fig. 5a) . To test the effects of FT671 on the p53-MDM2 axis in vivo, we used a MM.1S xenograft mouse model in which non-obese diabetic-severe combined immuno deficient (NOD-SCID) mice were implanted with MM.1S cells and randomized into different treatment groups. For pharmacodynamics studies, compound was administered once a day at 25 mg kg −1 , 75 mg kg
or 200 mg kg −1 via oral gavage. Individual mice were euthanized at different time points, and compound effects on p53 were monitored (Fig. 5b,  Extended Data Fig. 8e ). Mirroring the studies in cell lines (Fig. 4 , Extended Data Fig. 8a-d ), p53 stabilization in tumour tissue was observed shortly after a single dose of FT671 (Fig. 5b) . After 24 h, p53 levels returned to those of the vehicle-treated control (Fig. 5b, Extended  Data Fig. 8e) .
The in vivo anti-tumour growth activity of FT671 was tested in the MM.1S xenograft model after daily dosing via oral gavage at 100 mg kg −1 and 200 mg kg
. Treatment of mice with FT671 led to a significant dose-dependent inhibition of tumour growth (Fig. 5c) . FT671 was well-tolerated even at high doses, and no significant weight loss or cachexia was observed during the study (Fig. 5d ).
Conclusion
Our identification of highly specific USP7 inhibitors, including the nanomolar-potency, non-covalent compound FT671, shows that USPs are tractable drug targets for cancer and other diseases 36, 37 . The underlying concept of targeting otherwise intractable, undruggable proteins by modulating their half-life is an important emerging strategy in drug discovery 38, 39 . It has been unclear whether the structurally highly similar USP DUBs would be amenable to the discovery of specific small molecules. We show not only that this is possible, but also that the remarkably dynamic USP catalytic domain reveals interaction sites for small molecules that could not have been predicted from available structures. The generation of similarly selective inhibitors for other family members will unveil the full therapeutic potential of DUB inhibitors.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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MethOdS
No statistical methods were used to predetermine sample size, and investigators were not blinded to allocation during experiments and outcome assessment. Protein expression and purification for USP7 CD proteins. His-tagged USP7 CD (residues 208-560) and the corresponding F291N, Q297A and Y465N pointmutation constructs were cloned into the pETNHT-1 vector and expressed in Escherichia coli Rosetta2 cells. Cells were grown in TB buffer at 37 °C to an OD 600 nm value of 0.6, induced with 0.5 mM IPTG and incubated overnight at 15 °C.
The cell pellet was resuspended in lysis buffer A (50 mM HEPES, pH 7.5, 300 mM NaCl, 1 mM dithiothreitol (DTT), 15 mM imidazole, 5 mM benzamidine, 1 mM AEBSF, 500 U benzonase) and lysed using a Constant Systems cell disruptor. Insoluble material was removed by centrifugation and the supernatant was loaded onto a HiTrap TALON crude column (GE Healthcare) equilibrated with Ni buffer A (50 mM HEPES, pH 7.5, 300 mM NaCl, 1 mM DTT, 15 mM imidazole) and washed with buffer A and 45 mM imidazole until A 280 nm reached baseline. The protein was eluted with Ni buffer B (50 mM HEPES, pH 7.5, 300 mM NaCl, 1 mM DTT, 300 mM imidazole) and further purified using a HiLoad 26/60 Superdex 75 column (GE Healthcare) equilibrated with SEC buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM DTT). The protein was concentrated to approximately 20 mg ml , flash-frozen in liquid nitrogen and stored at − 80 °C. Chemical synthesis of USP7 compounds. FT671 and FT827 were prepared in agreement with the procedures described in detail previously 21 . The chemical synthesis is described in the Supplementary Information, and the characterization data can be found in Supplementary Data. Surface plasmon resonance. Studies of binding kinetics were performed on a Biacore T200 (GE Healthcare). His-tagged USP7 CD wild-type and mutant proteins, and the His-tagged PH domain of Akt (non-DUB negative control) were immobilized in 10 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM CaCl 2 , 1 mM β -mercaptoethanol, 5% (v/v) glycerol, 0.01% Triton X-100 on a Biacore Series S NTA chip through N-terminal His tag capture, followed by amine-coupling with EDC/NHS/ethanolamine as per the manufacturer's instructions, aiming for an immobilization level of 10,000 RU.
Compounds were tested in duplicate in twofold dilution series in immobilization buffer supplemented with 3% (v/v) DMSO, with a flow rate of 30 μ l min
, a contact time of 60 s, and a dissociation time of 300 s. A solvent correction curve from 2.4-3.8% (v/v) DMSO was included. Ubiquitin at 20 μ M was injected between compounds as a positive control, and ten-point dilution curves of ubiquitin from 500 μ M were included before and after the compounds to ensure surface integrity was retained throughout.
Analysis was performed using the Biacore Evaluation software version 3.0 using a kinetic fit and a 1:1 binding model with the R max fit locally. Representative curves were exported and re-plotted in GraphPad Prism.
The fact that the irreversible compound FT827 displays reversible behaviour is consistent with its measured k inact value (0.0003 s −1 corresponding to t 1/2 = 38.5 min) and the short association time (60 s = 0.026 × t 1/2 ), from which the percentage of complexes forming a covalent bond would be predicted to be 100 − (100/2 0.026 ) = 1.8%. Circular dichroism. Analysis was carried out at the University of Cambridge's Biophysics Facility, using an Aviv Model 410 Circular Dichroism Spectrometer. Wild-type USP7 CD , USP7 CD (F291N), USP7 CD (Q297A) and USP7 CD (Y465N) were buffer exchanged into circular dichroism buffer (10 mM potassium phosphate, pH 7.5, 100 mM potassium fluoride, 1 mM DTT) using a Zeba Spin column, before dilution to approximately 0.2 mg ml . Circular dichroism experiments were carried out at room temperature, reading at wavelengths from 250 nm to 189 nm in 1-nm steps, with an averaging time of 3 s, setting time of 0.33 s, and 3 scans per wavelength. Data from scans were averaged, buffer-subtracted, smoothed and exported to GraphPad Prism for analysis. In vitro USP7 activity assay. Fluorescence intensity measurements were used to monitor the cleavage of a monoubiquitinated ubiquitin-rhodamine substrate 20 . All activity assays were performed in black 384-well ProxiPlates (PerkinElmer) in 20 mM Tris, pH 8.0, 2 mM CaCl 2 , 1 mM reduced glutathione, 0.01% (v/v) Triton X-100, 0.01% (v/v) Prionex and an assay volume of 10 μ l.
To determine compound IC 50 values, compounds were diluted in 100% DMSO in threefold 12-point dilution series from 100 μ M. 100 nl of 100-fold concentrated solutions were dispensed into black 384-well Proxiplates (Perkin Elmer) using an Echo (Labcyte). 25 nM ubiquitin-rhodamine 110 (Boston Biochem), along with recombinant USP7 CD (3 nM), or USP7 C-term (30-125 pM, depending on batch activity) were added and the plates incubated at room temperature for 1 h. The reaction was terminated by adding 2.5 μ l citric acid to a final concentration of 10 mM before measuring fluorescence intensity on a Pherastar (BMG Labtech) with a 485 nm excitation/520 nm emission optic module.
To determine K m /k cat values, recombinant USP7 CD (3 nM), USP7 CD (F291N) (0.2 nM), USP7 CD (Q297A) (16 nM) or USP7 CD (Y465N) (100 nM) were incubated at room temperature for 1 h with a twofold 15-point dilution series of ubiquitinrhodamine 110 (Boston Biochem) from a top concentration of 5 μ M. Upon addition of the substrate, fluorescence intensity was monitored kinetically on a Pherastar (BMG Labtech) with a 485 nm excitation/520 nm emission optic module. Relative fluorescent units were converted to picomoles of ubiquitin-rhodamine per mole enzyme, by normalizing to 100% substrate conversion at each concentration of ubiquitin-rhodamine, estimated in the presence of excess enzyme. Converted data were plotted in Graphpad Prism and the initial rate was determined from the slope of a linear fit of the early part of the curve (over approximately 10 min). Initial rates were plotted against substrate conversion and fitted to a k cat fit in Graphpad Prism. k inact /K i determination. For the covalent compound FT827, a k inact /K i assay was carried out using 125 pM USP7 C-term as described above. Upon addition of the substrate, fluorescence intensity was monitored kinetically over 3 h. Analysis was performed in ActivityBase (ID Business Solutions Limited). Kinetic progress curves were fitted to equation y = y max (1 − exp(−k obs .x)) to determine the k obs value. The k obs value was then plotted against the inhibitor concentration and fitted to the equation y = k inact /(1 + (K i /x)) to determine k inact and K i values. In vitro compound specificity panel. DUBprofiler assays were performed by Ubiquigent. FT671 was tested at 50 μ M using 100 nM ubiquitin-rhodamine 110 as the substrate. For most enzymes, the K m value exceeds the substrate concentration. For USP11, USP15, USP20, UCHL1, UCHL3 and OTUD3, the K m was similar to or lower than the substrate concentration, and the potency of competitive inhibitors may be underestimated.
Linearity of enzyme activity through the assay incubation time was validated for each DUB enzyme by Ubiquigent. All assays were operating at < 40% substrate conversion and data are reported as a percentage of the activity of the enzyme in the presence of the test compound relative to 'plus' (100% activity) and 'minus' (0% activity) DUB enzyme controls. Four 'plus' enzyme control wells and 'product modulator' control wells were run on each DUBprofiler assay plate. Eight 'minus' enzyme control wells were run on each DUBprofiler assay plate. DUB profiling assays using ubiquitin-based active site directed probes. Molecular probes based on the ubiquitin scaffold were generated and used essentially as described 7, 23 with some modifications. In brief, HA-UbC2Br was synthesized by expressing the fusion protein HA-Ub 75 -intein-chitin binding domain in E. coli BL21 strains 22 . Bacterial lysates were prepared, and the fusion protein purified over a chitin-binding column (NEB Labs). HA-Ub 75 -thioester was obtained by incubating column material with mercaptosulfonate sodium salt (MESNa) overnight at 37 °C. HA-Ub 75 -thioester material was desalted against PBS using a PD10 column according to the manufacturer's instructions (GE Healthcare). 500 μ l of 1-2 mg ml −1 of HA-Ub 75 -thiolester was incubated with 0.2 mmol of bromoethylamine at pH 8-9 (adjusted by adding NaOH) for 20 min at room temperature, followed by a desalting step against phosphate buffer (pH 8) as described above. Ubiquitin probe material was concentrated using 3,000 Da molecular mass cutoff filters (Sartorius) to a concentration of approximately 1 mg ml −1 , and kept as aliquots at − 80 °C until use. DUB competition assays with cell extracts and with cells (in situ). Human breast cancer MCF7 cells were cultured in DMEM medium supplemented with 10% FCS, 1% penicillin/streptomycin and 1% glutamine at 37 °C and 5% CO 2 . Crude extracts were prepared as described previously using glass-bead lysis in 50 mM Tris, pH 7.4, 5 mM MgCl 2 ·6H 2 O, 0.5 mM EDTA, 250 mM sucrose and 1 mM DTT 7, 23 . For experiments with crude cell extracts, 50 μ g of MCF7 cell lysate was incubated with different concentrations of either FT671 or FT827 for 1 h at 37 °C, followed by addition of 1 μ g HA-UbC2Br and incubation for 5 min at 37 °C. Incubation with the ubiquitin probe was optimized to minimise replacement of non-covalent inhibitor FT671 by the covalent probe. Samples were subsequently boiled in reducing SDS-sample buffer, separated by SDS-PAGE and analysed by western blotting using anti-HA (12CA5, Roche 11583816001, 1:2,000), anti-USP7 (Enzo PW0540, 1:1,000), anti-β -actin (Abcam ab8227, 1:2,000), IRdye 800CW goat anti-rabbit (925-32211, Li-COR, 1:10,000) or goat anti-mouse (925-332210,
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Li-COR, 1:10,000) antibodies. 5 × 10 6 intact MCF7 cells were incubated with different concentrations of inhibitors in cultured medium for 4 h at 37 °C, followed by glass-bead lysis, labelling with the HA-UbC2Br probe and analysis by SDS-PAGE and western blotting as described above. Mass spectrometry-based DUB inhibitor profiling assays. Ubiquitin probe pulldown experiments in the presence of different concentrations of the inhibitors FT671 and FT827 were performed essentially as described 7, 23 with some modifications. In brief, immunoprecipitated material was subjected to in-solution trypsin digestion 41 and desalted using C18 SepPak cartridges (Waters) according to the manufacturer's instructions. Digested samples were analysed in triplicate by nano-UPLC-MS/MS using a Dionex Ultimate 3000 nano UPLC with EASY spray column (75 μ m × 500 mm, 2 μ m particle size, Thermo Scientific) with a 60 min gradient of 0.1% (v/v) formic acid in 5% (v/v) DMSO to 0.1% (v/v) formic acid to 35% (v/v) acetonitrile in 5% (v/v) DMSO at a flow rate of approximately 250 nl min −1 (600 bar per 40 °C column temperature). Mass spectrometry data were acquired with an Orbitrap Q Exactive High Field (HF) instrument in which survey scans were acquired at a resolution of 60,000 at 400 m/z and the 20 most abundant precursors were selected for CID fragmentation. From raw mass spectrometry files, peak list files were generated with MSConvert (Proteowizard v.3.0.5211) using the 200 most abundant peaks/spectra. The Mascot (v.2.3, Matrix Science) search engine was used for protein identification at a false discovery rate of 1%, mass deviation of 10 p.p.m. for MS1 and 0.06 Da (Q Exactive HF) for MS2 spectra, Cys carbamidylation as fixed modification, Met oxidation and Gln deamidation as variable modification. Searches were performed against the UniProtKB human sequence database (retrieved 15 October 2014). Label-free quantification was performed using MaxQuant Software (v.1.5.2), and data were further analysed using GraphPad Prism software (v.7.0) and Microsoft Excel 2010. For the statistical analysis in Fig. 1e and f, we applied two-way ANOVA tests including multiple comparison testing via the Dunnett method available through the GraphPad Prism software. P value style is GraphPad: NS, P = 0.1234, * P = 0.0332, * * P = 0.0021, * * * P = 0.0002, * * * * P < 0.0001. Expression and purification of USP7 CD for crystallography. Glutathione S-transferase (GST)-tagged USP7 CD (residues 208-560) was cloned into the pGEX4T vector and expressed in E. coli Rosetta2 cells as described previously 24 . Cells were grown in TB buffer at 37 °C to an OD 600 nm of 0.6, induced with 0.4 mM IPTG and incubated overnight at 18 °C.
The cell pellet was resuspended in lysis buffer C (50 mM HEPES, pH 7.5, 300 mM NaCl, 1 mM DTT, 5 mM benzamidine, 1 mM PMSF) and lysed using a Constant Systems cell disruptor. Insoluble material was removed by centrifugation and the supernatant was loaded onto a column packed with Glutathione Sepharose 4B beads (GE Healthcare) and washed with GST buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM DTT) until A 280 nm reached the baseline.
The GST tag was cleaved off-column using thrombin and removed by reapplying the sample onto the GSH column. USP7 CD was then separated from thrombin using Benzamidine Sepharose beads (GE Healthcare), and purified further by gel filtration (Superdex 200, GE Healthcare in 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM DTT). Protein was concentrated to 17.5 mg ml Data collection and refinement. Data for the USP7-FT671 and USP7~ FT827 complex structures were collected at Diamond Light Source (Harwell, UK), beamline I03 and I04, respectively, at 100 K, and processed to 2.35 Å and 2.33 Å resolution, respectively, using the Xia2 pipeline 42 . Structures were solved by molecular replacement with PHASER 43 and human USP7 CD (PDB code 1NB8 24 ) as the search model. The model was rebuilt using COOT 44 and refined using REFMAC5 45 . Data collection and refinement statistics are shown in Extended Data Table 2 . Ramachandran statistics are as follows: USP7-FT671: 95.3% favoured, 4.2% allowed, 0.5% outliers and USP7~ FT827: 94.8% favoured, 4.7% allowed, 0.5% outliers. Figures were generated with PyMol (http://www.pymol.org), and Molecular Operating Environment (MOE) (v.2013.08, Montreal, Canada). Cellular studies with USP7 inhibitors. MM.1S cells were acquired from ATCC (CRL-2974) and their identity was authenticated using STR analysis. HCT116 cells were acquired from ATCC (ATCC-CCL-247, October 2016). IMR-32 were acquired from Sigma (86041809, January 2016). MCF7 were acquired from ATCC (HTB-22). U2OS were acquired from ATCC (HTB-96, authenticated in March 2017). HCT116, MCF7 and U2OS cells were authenticated using STR analysis. Cell lines used in this study were verified to be mycoplasma negative before undertaking any experiments with them.
MM.1S cells (ATCC) were grown in log phase in RPMI-1640 supplemented with 10% fetal bovine serum and antibiotic/antimycotic solution. FT671 was added to cells at a final concentration of 10 μ M for 0 h, 2 h, 4h, 8 h or 24 h, as indicated. Cells were collected from both the liquid fraction and the adherent fraction by collecting, washing with chilled PBS and snap-freezing at − 80 °C. Cell lysate was prepared for western blotting by lysing with RIPA lysis buffer (Boston Bioproducts), followed by separation by SDS-PAGE and transfer to PVDF membrane using the iBlot2 system (Life Technologies). Blots were probed with antibodies against MDM2 (IF2, Calbiochem), p53 (DO-1, Santa Cruz Biotechnology), p21 (12D1, Cell Signaling Technologies) and β -actin (13E5, Cell Signaling Technologies). Membranes were developed using Pierce ECL western blotting substrate (Fisher) and imaged on the Amersham Bioluminescent Imager (GE Healthcare).
HCT116, U2OS and IMR-32 cells were cultured in DMEM medium with Glutamax supplemented with 10% FBS, 1% nonessential amino acids, and 1% penicillin/streptomycin (Gibco). Compound-resistant cell lines. GFP-USP7 was subcloned from pEGFP-C-GW-USP7 into pCDNA5-FRT-TO (Invitrogen). The coding sequences for F291N and Q297A were subcloned from pETNHT_USP7 K208-E560 (F291N) and pET-NHT_USP7 K208-E560 (Q297A) plasmids into pCDNA5-GFP-USP7.
HCT116 Flp-In TRex cells (gift from S. Taylor) were cultured in DMEM with Glutamax supplemented with 10% FBS, 1% nonessential amino acids solution, 1% penicillin/streptomycin, 10 μ g ml −1 zeocin and 4 μ g ml −1 blasticidin (Invitrogen). HCT116 Flip-In Trex cells were transfected with Lipofectamine LTX, with Plus Reagent (Invitrogen), with pOG44 and either pEF5-GFP, pCDNA5-GFP-USP7WT, pCDNA5-GFP-USP7F291N or pCDNA5-GFP-USP7Q297A. Hygromycin B (50 μ g ml −1 , Invitrogen) was added two days after transfection and cells were kept under selection for three weeks.
Stably transfected HCT116 Flip-In Trex GFP, GFP-USP7(WT), GFP-USP7(F291N) and GFP-USP7(Q297A) cells were incubated with 0.1 μ g ml
doxycycline for 3 h, and then treated with 1 μ M and 3 μ M of FT671 or vehicle for 4 h in presence of doxycycline. Cells were lysed with RIPA buffer supplemented with mammalian protease inhibitor (Sigma) and phosphatase inhibitor cocktails (Roche). Protein lysates were resolved by SDS-PAGE (10% gel, BioRad), transferred to nitrocellulose (Amersham Protran, GE Healthcare). Membranes were probed as indicated. Quantitative PCR analysis. MM.1S or HCT116 cells (ATCC) were grown, in log phase, in RPMI-1640 supplemented with 10% fetal bovine serum and an antibiotic/ antimycotic solution. FT671 was added to cells at a final concentration of 10 μ M for 0, 2, 4, 8 or 24 h, as indicated. Cells were collected from both the liquid fraction and the adherent fraction by collecting, washing with chilled PBS and snap-freezing at −80 °C.
RNA was harvested from cells using the RNeasy Kit (Qiagen) and quantified by Nanodrop. Transcripts were amplified and quantified using the TaqMan RNAto-Ct 1-step kit (Life Technologies) with TaqMan Probe sets on the QuantStudio7 Flex (Life Technologies) according to the manufacturer's instructions. TaqMan primer sets were used for the following genes, CDKN1A (Hs00355782_m1, Life Technologies), BBC3 (Hs00248075_m1), MDM2 (H200540450_s1), RPS27L (Hs00955038_g1), Myc (Hs00153408_m1), MCL1 (Hs01050896_m1), GAPDH (Hs0392907g1). Cycle number and fold-change were quantified using the software for the QuantStudio7 Flex and plotted in Prism 7.0.
Meso Scale Discovery MDM2 ubiquitination assay. MM.1S cells were plated in a 96-well format (26,700 cells per well) and treated at the same time with compound FT671 (final concentration 10 μ M, 0.1% DMSO) and proteasome inhibitor MG132 (final concentration 25 μ M) (AlfaAesar, J63250LB0) or 0.1% DMSO, and harvested at indicated time points. Cells were lysed and cell pellets were processed with the Meso Scale Discovery assay kit for ubiquitinated and total MDM2 in whole cell lysate (K15168D) according to the manufacturer's instructions. The measured ratio of ubiquitinated versus non-ubiquitinated total MDM2 from a triplicate experiment was plotted with Graphpad Prism. Cell viability studies. MM.1S were plated at a starting density of 3,500 cells per well in 40 μ l of RPMI-1640 (Corning) supplemented with 2 mM l-glutamine, 10% fetal bovine serum (Corning), 1% penicillin/streptomycin and 10 mM HEPES, pH 7.4. Cells were plated in 384-well black plates (Corning 3712) and incubated at 37 °C, 5% CO 2 in a humidified atmosphere for 12 h before DMSO-solubilised FT671 was added using an ECHO 525 acoustic dispenser. The final DMSO concentration was 0.5% (v/v). After compound addition, cells were incubated for 120 h at 37 °C, 5% CO 2 in humidified atmosphere. Experiments were performed in triplicate, simultaneously on different plates.
The viability assay was performed using CellTiter-Glo 2.0 (Promega) following the manufacturer's instructions. Luminescence was measured using an Envision plate reader (PerkinElmer) and normalized to the samples treated with 0.5% (v/v) DMSO. The IC 50 values were calculated using nonlinear regression algorithms in ActivityBase (ID Business Solutions Limited). MM.1S xenograft studies. Six-to-eight-week-old female NOD-SCID mice (Vital River Laboratory Animal Technology Co) were irradiated (2 Gy) with a Co60 irradiator source 24 h before subcutaneous inoculation of 5 × 10 6 MM.1S tumour cells in 1:1 mixture of RPMI-1640 and Matrigel. The efficacy study was initiated when tumours had reached an average volume of 159 mm 3 . Tumour-bearing mice were randomly assigned to treatment groups such that each treatment group had the same average tumour volume. Mice received a lead-in dose of 25 mg kg −1 of FT671 24 h before starting on the dosing regimen of 100 or 200 mg kg −1 FT671 (once a day, per os by oral gavage). 10% DMA, 90% PEG400 served as a vehicle control (n = 9 mice per group). For the statistical analysis of differences in tumour volumes between treatment groups, a two-way ANOVA with repeated measures was performed followed by correction for multiple comparisons using statistical hypothesis testing (Tukey).
For the pharmacokinetic/pharmacodynamic (PK/PD) study, a single adminis tration of 200, 75 or 25 mg kg −1 FT671 was given per os by oral gavage when tumours had reached an average volume of 318 mm 3 . 10% DMA, 90% PEG 400 served as a vehicle control (n = 5 mice per group per time point). Tumour samples were collected at 0.5 h, 2 h, 6 h and 24 h time points and flash-frozen for subsequent analysis. Vehicle control samples were obtained at the 24 h time point.
For xenograft tumour tissue analysis, flash-frozen tissue samples were lysed in Tris lysis buffer (Meso Scale Discovery) complemented with protease and phosphatase inhibitors (Roche). p53 levels were analysed from 20 μ g of protein per sample by western blotting with anti-p53 (Santa Cruz sc-126, 1:200) and anti-p21 antibodies (Cell Signaling Technology 4970, 1:1,000). β -Actin (Cell Signaling Technology 2946, 1:1,000) was used to normalize p53 levels. Secondary antibodies were horseradish peroxidase (HRP)-conjugated anti-rabbit (Cell Signaling Technology 7074, 1:1,000) and anti-mouse (Cell Signaling Technology 7076, 1:1,000). ECL chemiluminescence detection reagents were used for detection and target bands were analysed using FluoChem FC2 software. Animal experiments. All animal experiments were performed at Pharmaron (Beijing, China). All animal experiments were performed according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of Pharmaron (Beijing, China) following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The protocol defines 3,000 mm 3 as the maximum tumour volume for a humane endpoint and animals with larger tumours were euthanized. Data availability. FT671 and FT827 are available from FORMA Therapeutics. All reagents are available upon reasonable request from the corresponding authors. Crystallographic coordinates and structure factors have been deposited with the Protein Data Bank (PDB) under accession codes 5NGE (USP7-FT671) and 5NGF (USP7~ FT827). Mass spectrometry data are available via ProteomeXchange with identifier PXD006418 and can also be found in Supplementary Tables 1 and 2 . Uncropped images of all gels and blots in this study can be found in Supplementary Fig. 1 . Chemical characterization of FT671 and FT827 can be found in the Supplementary Information (and Supplementary Data). Source Data are provided for animal experiments (Fig. 5b-d 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
See the methods section for details. Xia2, Phaser, Coot, Refmac, Pymol, Molecular Operating Environment (MOE), Biacore T200 Evaluation Software, FluoChem FC2, Microsoft Excel, Graphpad Prism, MaxQuant, ActivityBase.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
a. State the source of each eukaryotic cell line used.
MM.1S cells were acquired from ATCC (Manassas, VA, CRL-2974) and their identity was authenticated using STR analysis. HCT116 cells were acquired from ATCC (ATCC-CCL-247, October 2016). IMR-32 were acquired from Sigma (cat. number 86041809, January 2016). MCF7 were acquired from ATCC (HTB-22). U2OS were acquired from ATCC (HTB-96, authenticated in March 2017). HCT116, MCF7 and U2OS cells were authenticated frequently.
b. Describe the method of cell line authentication used. Authentication was done using STR analysis.
c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines are frequently tested for mycoplasma contamination. Cell lines used in this study were verified to be mycoplasma negative before undertaking any experiments with them.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cells were used. All cells displayed homogeneous characteristic morphology.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Studies used 6-8 week old female NOD SCID mice (Vital River Laboratory Animal Technology Co, Beijing, China) which were irradiated (200 rads) with a Co60 irradiator source 24 h prior to subcutaneous inoculation of tumor xenografts. All animal experiments were performed at Pharmaron (Beijing, China). All the animal experiments were performed according to guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of Pharmaron (Beijing, China) following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
not applicable.
